Placebo controlled randomised trials showed that sodium-glucose cotransporter-2 (SGLT-2) inhibitors are cardioprotective and kidney protective among people with type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and diabetes mellitus.